UK Medicines Information
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Information type:
Randomised controlled trials
Source:
New England Journal of Medicine
Specialities:
Musculo-skeletal disorders
Summary
RCT (n=527) in patients with rheumatoid arthritis and an inadequate response to biologic DMARDs found that baricitinib at a daily dose of 4mg was linked to clinical improvement at 12 weeks vs. placebo (ACR20 response: 55% vs. 27%, respectively; p<0.001).
UKMi comment
Baricitinib, an oral Janus kinase 1 and 2 inhibitor, was filed for approval in the US in Jan 2016.
Related links: